Boditech Med Inc

Chart & Performance

D1W1MN

P/E

11.27

P/S

2.22

EPS

1,240.93

Div Yield, %

1.43%

Shrs. gr., 5y

-0.93%

Rev. gr., 5y

13.67%

Revenues

138.16b

+2.94%

Net income

27.26b

+5.06%

CFO

24.88b

-27.47%

Dividend

Mar 29, 2024200 KRW/sh

Profile

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.

URL

https://www.boditech.co.kr/en

IPO date

Dec 29, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	138,160,173 2.94%	134,219,240 13.67%	118,076,843 -25.13%
Cost of revenue	86,523,420	80,782,350	77,597,438
Unusual Expense (Income)
NOPBT	51,636,753	53,436,889	40,479,404
NOPBT Margin	37.37%	39.81%	34.28%
Operating Taxes	5,180,911	4,898,834	1,683,777
Tax Rate	10.03%	9.17%	4.16%
NOPAT	46,455,842	48,538,055	38,795,627
Net income	27,260,388 5.06%	25,946,636 7.43%	24,151,534 -45.56%
Dividends	(4,395,079)	(3,295,169)	(4,269,927)
Dividend yield	1.19%	0.73%	1.86%
Proceeds from repurchase of equity	(2,829,041)	12,300	(7,077,621)
BB yield	0.77%	0.00%	3.09%
Debt
Debt current	7,847,708	7,917,421	5,725,203
Long-term debt	5,496,648	3,859,378	3,170,044
Deferred revenue			870,044
Other long-term liabilities	552,407	47,904	480,856
Net debt	(80,826,732)	(86,271,851)	(63,222,028)
Cash flow
Cash from operating activities	24,878,655	34,299,696	23,068,408
CAPEX	(11,426,876)	(5,630,193)	(16,905,123)
Cash from investing activities	(11,977,874)	(16,122,485)	(24,454,171)
Cash from financing activities	(7,976,063)	(1,937,701)	(10,161,601)
FCF	30,067,276	49,227,325	19,446,745
Balance
Cash	61,715,309	76,197,828	60,459,055
Long term investments	32,455,779	21,850,823	11,658,220
Excess cash	87,263,079	91,337,689	66,213,433
Stockholders' equity	222,477,211	197,539,587	176,740,639
Invested Capital	134,645,586	116,694,541	117,222,285
ROIC	36.97%	41.50%	37.22%
ROCE	21.96%	25.62%	21.94%
EV
Common stock shares outstanding	21,942	21,968	22,364
Price	16,780.00 -18.15%	20,500.00 100.00%	10,250.00 -38.99%
Market cap	368,183,438 -18.24%	450,346,501 96.46%	229,229,719 -40.46%
EV	300,139,987	375,292,959	177,283,430
EBITDA	60,078,746	61,668,408	47,951,906
EV/EBITDA	5.00	6.09	3.70
Interest	352,502	350,388	203,924
Interest/NOPBT	0.68%	0.66%	0.50%